To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Cerebrospinal fluid HIV-1… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.

Journal article
Authors Aylin Yilmaz
Dietmar Fuchs
Lars Hagberg
Ulrika Nillroth
Lars Ståhle
Jan-Olof Svensson
Magnus Gisslén
Published in BMC infectious diseases
Volume 6
Pages 63
ISSN 1471-2334
Publication year 2006
Published at Institute of Biomedicine, Department of Infectious Medicine
Pages 63
Language en
Keywords Adult, Anti-HIV Agents, blood, cerebrospinal fluid, therapeutic use, CD4 Lymphocyte Count, Drug Therapy, Combination, Female, HIV Infections, drug therapy, HIV-1, metabolism, Humans, Immunoglobulin G, blood, cerebrospinal fluid, Male, Middle Aged, Nelfinavir, blood, cerebrospinal fluid, therapeutic use, Neopterin, cerebrospinal fluid, RNA, Viral, blood, cerebrospinal fluid, Saquinavir, blood, cerebrospinal fluid, therapeutic use, beta 2-Microglobulin, blood, cerebrospinal fluid
Subject categories Microbiology in the medical area


BACKGROUND: The way various antiretroviral drugs and drug combinations affect HIV-1 infection in the central nervous system is still largely unknown. The aim of this study was to determine the cerebrospinal fluid (CSF) steady-state concentrations of saquinavir and nelfinavir in relation to plasma concentrations, and to study their effect in combination with two nucleoside reverse transcriptase inhibitors (NRTIs) on CSF viral loads, intrathecal immunoactivation, and blood-brain barrier integrity. METHODS: Paired CSF and plasma samples from 8 antiretroviral-naïve HIV-1 infected patients starting combination therapy with saquinavir, nelfinavir, and two nucleoside analogues were collected prior to treatment, and again after approximately 12 and 48 weeks of antiretroviral therapy. Additional plasma samples were taken at weeks 2, 4, 8, 24, and 36. The concentrations of protease inhibitors were analysed, as were levels of HIV-1 RNA, CD4+ T-cell count, beta2-microglobulin, neopterin, albumin ratio, IgG index, and monocytic cell count. RESULTS: None of the patients in the study presented with HIV-1 RNA < 50 copies/mL in CSF or plasma prior to treatment, compared to 5/7 at the end of the study. Signs of cell-mediated intrathecal immunoactivation, measured by neopterin and beta2-microglobulin, decreased significantly in both CSF and serum, although only 1/7 reached normal CSF neopterin levels after 48 weeks of treatment. There was no significant reduction of albumin ratio, IgG index or CSF monocytic cell count. Saquinavir median (range) concentrations were < 2.5 (< 2.5-96.0) nM unbound in plasma, and < 2.5 (< 2.5-9.0) nM total in CSF. Nelfinavir median (range) concentrations were 10.0 (< 2.0-31.0) nM unbound in plasma, and < 2.0 (< 2.0-23.0) nM total in CSF. Saquinavir and nelfinavir were detectable in 7/15 and 9/15 CSF samples, respectively. CONCLUSION: Saquinavir and nelfinavir, in combination with two NRTIs, decrease the CSF viral load and, to a lesser extent, intrathecal immunoactivation. We found reasonably high CSF concentrations of nelfinavir, but suboptimal concentrations of saquinavir.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?